Malignant thoracic mesothelioma (MPM) has made significant progress in 15 years! Opdivo-Yervoy immune portfolio first-line therapy significantly extends total survival!

!--ewebeditor:page title"--August 09, 2020 // -- Pershing Meishiguibao (BMS) recently announced the evaluation of anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab) , Navoliu monotherapy) combined anti-CTLA-4 therapy Yervoy (ipilimumab, eplimma) first-line treatment of malignant pleural mesothelioma (MPM) key Phase III CheckMate-743 study total survival (OS) data.
results showed that Opdivo-Yervoy double immunotherapy (OY combination) showed long-lasting survival benefits compared to chemotherapy.
results were presented on August 8 at the Virtual Presidential Symposium at the 21st World Lung Cancer Congress 2020 (IASLC WCLC), hosted by the International Lung Cancer Research Association.
noteworthy, CheckMate-743 is the first and only Phase III trial in which first-line immunotherapy significantly improves the survival of MPM patients.
to date, the Opdivo-Yervoy combination has shown clinical benefits in six different tumor types, including long-lasting, superior total survival (OS) compared to chemotherapy in two thoracic cancers.
Opdivo-Yervoy is a unique combination of two immunos checkpoint inhibitors with potential synergistic mechanisms for two different checkpoints (PD-1 and CTLA-4) to help destroy tumor cells: Yervoy helps activate and multiply T-cells, while Optivo helps existing T-cells detect tumors.
some of the T cells stimulated by Yervoy can become memory T cells, which may allow for long-term immune response.
In terms of U.S. regulation, Opdivo-Yervoy combination therapy has been approved for six treatments for six of the five cancers (melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer). Paul Baas, M.D., Department of Chest Oncology,
Netherlands Cancer Institute and Leiden University, said: "Malignant thoracic mesothelioma is an invasive cancer with a five-year survival rate of less than 10 per cent and has shown resistance to many clinical treatments.
To now, for the first time, we have evidence that in all types of malignant thoracic mesothelioma (epiderm and non-epiderm) first-line treatments, double immunotherapy has shown superior overall survival benefits over chemotherapy

CheckMate-743 data supports Optivo-Yervoy's potential as a new standard of care. Sabine Maier, Vice President of Clinical Development for Pershinger's Biopic Oncology,
, said, "These data on malignant thoracic mesothelioma are based on the long-term efficacy of Optivo in the treatment of non-small cell lung cancer and further demonstrate the potential of this dual immunotherapy to change survival expectations in patients with thoracic cancer."
for more than 15 years, no new systemic treatment for malignant thoracic mesothelioma has been approved.
look forward to discussing the positive outcome of CheckMate-743 with global health authorities in the coming months.
" CheckMate-743 is an open-label, multi-center, randomized Phase III clinical trial that included 605 previously untreated, non-removable MPM patients, assessed the efficacy and safety of Optivo-Yervoy double immunotherapy for first-line treatments, and compared it with chemotherapy (Pemecet and cisplatin or capa).
, patients were randomly assigned to receive Opdivo-Yervoy (n-303) and chemotherapy (n-302).
Opdivo-Yervoy treatment group, Opdivo is given 3mg/kg every two weeks and Yervoy is given 1mg/kg every six weeks for 24 months or until the disease progresses or unacceptable toxicity occurs.
chemotherapy group, received cisplatin 75mg/m2 or capa APC 5 combined pemmicure 500mg/m2, 21 days for a total of 6 cycles, or until the disease progresses or unacceptable toxicity occurs.
end of the study was total survival (OS) for all randomized patients.
results showed that the study reached the main endpoint: opdivo-Yervoy group OS significantly improved compared to the chemotherapy group (middle LS: 18.1 months vs 14.1 months), and the risk of death was reduced by 26% (HR-0.74; 96.6% CI:0.60-0.91; p-0.002).
, the survival rate was 41% in the Opdivo-Yervoy group and 27% in the chemotherapy group.
histology is a recognized prognosis factor for mesothelioma, and non-epiderm patients usually have a poor prognosis.
in the CheckMate-743 study, Opdivo-Yervoy showed an increase in total survival in both non-epiderm and epiderm MPM, and greater survival benefits were observed in non-epiderm subgroups.
Specific data are: opdivo-Yervoy treatment of the middle OS of 18.7 months, non-epiderm OS of 18.1 months, chemotherapy treatment of the epiderm sample of patients with 16.5 months, non-epiderm patients of the middle OS of 8. 8 months (epiderm sample subgroup: HR?0.86?95%CI:0.69, 1.08); non-epiderm subgroup: HR?0.46?95%CI:0.31, 0.68).)
study, the safety of Opdivo-Yervoy's double immunotherapy was consistent with previously reported studies, and no new safety signals were observed.
malignant thoracic mesothelioma (MPM) is a rare and highly invasive tumor formed in the lung lining.
cause of the disease is exposure to asbestos.
MPM diagnosis is often delayed, and most patients are already in advanced or metastatic disease at the time of diagnosis, and the prognosis is usually poor: in patients with previously untreated advanced or metastatic MPM, the medium survival rate is about 1 year and the 5-year survival rate is about 10%.
!--/ewebeditor:page-!--ewebeditor:page title"--MPM is a devastating disease, and treatment progress has been limited over the past 15 years.
positive top-line results from the CheckMate-743 trial demonstrate the potential of the Opdivo-Yervoy combination drug programme for first-line treatment of MPM, and are another example of the efficacy and safety of this combination of dual immunotherapy found in a variety of tumor types.
Opdivo and Yervoy are both tumor immunotherapy (I-O), which uses the body's own immune system to fight tumors by targeting different regulatory elements in the immune system, with Opdivo targeting blocking the PD-1/PD-L1 path and Yervoy targeting blocking CTLA-4.
currently, Permistus is developing the Optivo-Yervoy immune combination for the treatment of multiple types of tumors.
Opdivo-Yervoy is the only dual immunotherapy approved by the FDA in the United States, which has a potential synergistic mechanism that targets two different immunization checkpoints (PD-1 and CTLA-4) and works in complementary ways.
In terms of U.S. regulation, Opdivo-Yervoy combination therapy has been approved for six treatments for six of the five cancers (melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer).
The two most recent approvals are non-small cell lung cancer (NSCLL), specifically: (1) Opdivo-Yervoy combination of first-line treatment without EGFR or ALK genomic tumor distortion metastatic or recurrent NSCLC patients;
() Source: Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Survival Survival Benefit vs. Changey in Patients with Formerly Untreated Malignant Pleural Mesothelioma !--/ewebeditor:page-page.